Overall Fundamental outlook

* LAURUSLABS makes the list of companies with the best technicals at present.

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Revenue projections:

Revenue projections for LAURUSLABS
Revenue projections for LAURUSLABS

With Laurus Labs Limited's revenues expected to fall below the previous year's, investors are likely to approach the stock with caution. Declining revenues can negatively affect profitability, which makes it harder for the company to maintain investor confidence and perform well in the market.

Financial Ratios:

currentRatio 1.224000
forwardPE 39.599556
debtToEquity 52.143000
earningsGrowth 2.104000
revenueGrowth 0.195000
grossMargins 0.553840
operatingMargins 0.180300
trailingEps 6.620000
forwardEps 23.370000

Laurus Labs Limited's current ratio being 1.224 suggests the company will have no issues paying off its short-term debt. With sufficient cash reserves and current assets, Laurus Labs Limited can easily cover its immediate liabilities, reflecting solid financial health.
LAURUSLABS's positive earnings and revenue growth suggest that the company is expected to expand its business. This reflects a healthy financial outlook, as LAURUSLABS's increasing profits and sales signal further growth in the near future.
LAURUSLABS's forward EPS being higher than its trailing EPS suggests that the company is expected to generate stronger profits this year. This points to improving financial performance, with LAURUSLABS anticipated to deliver better earnings than it did in the prior year.

Price projections:

Price projections for LAURUSLABS
Price projections for LAURUSLABS

Price projections for LAURUSLABS have been revised upward over time, signaling increasing optimism about the company's future. This steady increase reflects a positive outlook for LAURUSLABS's growth and market performance.

Recommendation changes over time:

Recommendations trend for LAURUSLABS
Recommendations trend for LAURUSLABS


With analysts leaning toward a sell bias for LAURUSLABS, investors should be cautious and make decisions based on a wider set of market indicators. This approach will help balance short-term concerns with longer-term market trends, providing a more holistic view of the stock.